Simpson Thacher & Bartlett and Lee & Li have advised a consortium led by KKR & Co on its $1.56 billion acquisition of Taipei-listed LCY Chemical, which was represented by Baker McKenzie.

This was the U.S. private equity firm’s first deal in Taiwan in more than a decade, and the largest private equity-backed transaction in the island, according to Reuters.

According to Reuters, KKR is leading a group of investors including LCY’s employees and family members of its founders. Upon closing, KKR will hold a majority and controlling interest in the chemicals company, which will be delisted from the Taiwan Stock Exchange.

The Simpson Thacher & Bartlett team was led by M&A partner Ian Ho, who was supported by partners Chris Lin, Makiko Harunari and Katharine Moir.

The Baker McKenzie team was led by partner Mark Tu.

Earlier this year, Simpson Thacher advised KKR on its first-ever sale of Japanese yen-denominated bonds, which raised 40.3 billion yen ($377 million).

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Nishimura continues SEA growth with energy partner

by Nimitt Dixit |

Japanese Big Six law firm Nishimura & Asahi has continued the planned expansion of its Southeast Asia offerings with the addition of energy-focused finance and M&A partner Sean Conaty.

GT, Goodwin act as Japan's Ono buys U.S. drugmaker for $2.4 bln

Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of  U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.

R&T, WongP, Lee & Lee advise on $595 mln TCM deal

by Nimitt Dixit |

Singapore law firms WongPartnership, Lee & Lee and Rajah & Tann (R&T), and R&T’s Malaysian member firm Christopher & Lee Ong have advised traditional Chinese medicine firm Eu Yan Sang International (EYS) and its shareholders on the sale of 86 percent of EYS’ shares.